SCHEMBL19544616

SCHEMBL19544616

CCOC(=O)c1cc(-c2ccc(C3OCCO3)cc2)n[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 8/20 0.65
▸ MAPT P10636 7/20 0.64
▸ RAB9A P51151 5/20 0.64
▸ NPC1 O15118 4/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ KMT2A Q03164 1/20 0.54
▸ ACR P10323 1/20 0.53
▸ HPGDS O60760 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ TP53 P04637 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ CA12 O43570 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19533624 0.83 ALPL (0.47) ALPLMAPTRAB9ANPC1POLB
SCHEMBL19624841 0.81 ALPL (0.60) ALPLTP53CA12CA9
SCHEMBL25168483 0.79 ALPL (0.76) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL2824803 0.79 ALPL (0.76) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL1413959 0.79 ALPL (1.00) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL19544602 0.79 MAPT (0.73) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL595997 0.79 ALPL (0.75) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL2888912 0.78 MAPT (1.00) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL1416809 0.78 MAPT (1.00) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL4712555 0.77 ALPL (0.73) ALPLMAPTRAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3246317-B1 BTK INHIBITOR HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) 2023-02-22 — — EP disclosed
US-10662174-B2 BTK inhibitor HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2020-05-26 — — US disclosed
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 — — EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662174-B2 BTK inhibitor BTK, SYK, LYN ALPL 3689/4885MAPT 418/4885RAB9A 1750/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN ALPL 3689/4885MAPT 418/4885RAB9A 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback